Clinical Studies
At ICON Dermatology and Aesthetics, being on the cutting edge is important. We work with industry to trial new aesthetic products, devices, and treatment protocols. If you are interested in participating in one of our clinical studies currently enrolling patients, please don’t hesitate to contact us. And, if you are interested in being notified of new clinical studies as they become available, please click the button below.
Enrolling Soon
A randomized, evaluator-blinded, no-treatment controlled, multicenter study to evaluate the effectiveness and safety of GP0114 for correction of wrinkles in the décolletage area.
Current (Enrollment Closed)
Multicenter, Evaluator-blinded, Randomized, Controlled Study of the Safety and Effectiveness of JUVÉDERM®
VOLITE XC Injectable Gel for Improvement in Neck Appearance.Complementary treatment of an injectable (similar to filler) to treat the horizontal lines on the neck. Patients must be over 18 years of age and should not have had treatment in that area for at least 6 months.
Completed
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the effectiveness and safety of Restylane Lyft with Lidocaine augmentation of the chin region to improve the chin profile.
A study to Evaluate the Effectiveness of BoNT/E for the treatment of Glabellar Lines.
A Randomized, Evaluator-Blinded, No-Treatment Controlled, Multicenter Study to Evaluate the Effectiveness and Safety of Sculptra Aesthetic for Correction of Cheek Wrinkles (closed 01/2022).
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination (closed 10/2020).
A Randomized, Evaluator-Blinded, No-Treatment Controlled, Multicenter Study to Evaluate the Effectiveness and Safety of Sculptra Aesthetic for Correction of Cheek Wrinkles (closed 01/2022).
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination (closed 10/2020).